Pregnancy outcome following gestational exposure to fluoroquinolones: A multicenter prospective controlled study

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 6, 1998, Pages 1336-1339

  Loebstein, Ronen ^a   Addis, Antonio ^a,b   Ho, Elaine ^a   Andreou, Roseann ^a   Sage, Suzanne ^c   Donnenfeld, Alan E ^d   Schick, Betsy ^d   Bonati, Maurizio ^b   Moretti, Myla ^a   Lalkin, Arieh ^a   Pastuszak, Anne ^a   Koren, Gideon ^a,e  

^a Motherisk Program   (Canada)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Teratogen Information Service   (United States)

^d Philadelphia Pregnancy Healthline   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPONTANEOUS ABORTION; TERATOGENICITY; THERAPEUTIC ABORTION;

EID: 0031833834     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.6.1336     Document Type: Article

References (13)

1. Berkovitch, M., A. Pastuszak, M. Gazarian, M. Lewis, and G. Koren. 1994. Safety of the new quinolones in pregnancy. Obstet. Gynecol. 84:535-538.
2. 1a. Canadian Pharmaceutical Association. 1997. Compendium of Pharmaceuticals and Specialties, p. 292-295. Canadian Pharmaceutical Association, Ottawa, Canada.
3. Chevais, M., P. Reinert, and M. C. Rondeau. 1987. Critical risk/benefit analysis of pefloxacine use in children under 15 years - the problem of arthralgias. Int. J. Clin. Pharmacol. Ther. Toxicol. 25:306-309.
4. Chysky, V. K., K. Kaplia, R. Hullmann, G. Arcieri, P. Schacht, and R. Echlos. 1991. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection. 19:289-296.
5. Danisovicova, A., M. Brezina, S. Belan, H. Kayserova, E. Kaiserova, I. Hruskovic, K. Orosova, S. Dluholucky, K. Galova, and E. Matheova. 1994. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy. A multicentre survey. Chemotherapy (Basel) 40:209-214.
6. Giamarellou, H., E. Kolokythas, G. Petrikos, J. Gazis, D. Aravatinos, and P. Sfikakis. 1989. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am. J. Med. 87(Suppl. 5A):49S-51S.
7. Ingham, B., D. W. Brentnall, E. A. Dale, and J. A. McFadzean. 1977. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol. Lett. 6:21-26.
8. Koren, G., M. Bologa, D. Long, Y. Feldman, K. Henderson, and N. H. Shear. 1989. The perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am. J. Obstet. Gynecol. 160: 1190-1194.
9. Koren, G., and A. Pastuszak. 1990. Prevention of unnecessary pregnancy termination by counselling women on drug, chemical and radiation exposure during the first trimester. Teratology 41:657-661.
10. Marden, P. M., D. W. Smith, and M. J. McDonald. 1964. Congenital anomalies in the newborn infant, including minor variations. J. Pediatr. 64:357-371.
11. Moore, K. L. 1988. The developing human. The W. B. Saunders Co., Philadelphia, Pa.
12. Schaefer, C., E. Amoura-Elefant, T. Vial, A. Ornoy, H. Garbis, E. Robert, E. Rodriguez-Pinilla, T. Pexieder, N. Prapas, and P. Merlob. 1996. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur. J. Obstet. Gynecol. 69:83-89.
13. Sophocles, A. M., and E. M. Brozovich. 1986. Birth control failure among patients with unwanted pregnancies. J. Fam. Pract. 22:45-48.